세계의 심혈관 기기 시장 : 제품별, 적응증별, 최종사용자별, 지역별 - 예측(-2029년)

The global cardiovascular devices market is USD 77.71 billion in 2024 and is projected to reach USD 110.39 billion by 2029, at a CAGR of 7.3 % during the forecast period.

The growth of the cardiovascular devices market is driven by several key factors, most notably the increasing prevalence of cardiovascular diseases (CVD) worldwide, advancements in minimally invasive procedures, and growing demand for improved patient outcomes and lastly shifting preference to remote monitoring. As rates of heart disease rise, the need for effective monitoring and treatments such as angioplasty, stenting, and valve replacements also increases where these devices are implemented. Technological innovations, including the development of drug-eluting stents, bioresorbable scaffolds and occluders, and advanced imaging technologies, have enabled safer and more precise procedures, which contribute to the market's growth.

"Based on the product type, the the cardiac imaging and diagnostic device segment holds a significant share the cardiovascular devices market."

Cardiac imaging and diagnostic devices include a range of medical technologies used to visualize the heart and assess its functions, enabling the detection, diagnosis, and monitoring of heart diseases. These devices provide detailed images of the heart's structure, blood flow, and electrical activity. The cardiac imaging and diagnostic devices segment is the one to grow at the highest rate in the cardiovascular devices market. This is due to growing global burden of cardiovascular diseases, advancing imaging technologies, rising importance of early diagnosis, and precision medicine. As it is CVDs remain the leading cause of mortality throughout the world, demands increasingly accurate and non-invasive diagnostic tools. Advancements like real-time 3D echocardiography, cardiac MRI, and AI-assisted imaging solutions also significantly enhance the diagnostic efficiency concerning the quality of care for patients and lead to the adoption of such devices among healthcare providers. Apart from this, prevalence of chronic diseases, which increases the risk for heart-related issues, further presses upon continuous cardiac monitoring and the demand for early detection. Government initiatives and healthcare reimbursement policies in the advanced as well as emerging markets drive the adoption of advanced imaging devices. Telehealth capabilities and portable diagnostic devices also make it more accessible, supporting broader market penetration.

"The Coronary artery disease segment holds the largest market share in cardiovascular devices market."

Coronary heart disease occurs when plaque (atherosclerosis) builds up inside the coronary arteries, that feed blood to the heart muscle, and narrows or blocks them. Thereby, breathlessness or angina may result from heart muscle not receiving enough oxygen rich blood. In extreme cases, heart attack or myocardial infarction may occur due to a total blockage of the coronary artery.Some of the major causes for CAD include an unhealthy lifestyle, including a diet full of saturated fats, lack of exercise, and smoking, which cause damage to the arteries over time. Other factors that contribute to this condition include hypertension, high cholesterol levels, diabetes, and obesity, all of which further the development of plaque. Genetic disposition, age, and chronic stress also add to the development of CAD due to their general impact on the heart and blood vessels. The increasing incidence of the above factors coupled with hightened awareness among the popuation regarding therse diseases would aid in market growth.

"Based on the end user, Others segment is expected to grow by the significant CAGR in the cardiovascular devices market.

The "others" segment, which includes applications like general health checkup, fitness, and wellness monitoring, intraoperative monitoring, and post-op care, is growing the fastest in the cardiovascular device market. This is because of increased focus on preventive care, personalized medicine, and holistic patient care. With the ever-growing awareness on the importance of regular cardiovascular monitoring, there are growing demands for wearable and connected devices which measure parameters including heart rate, blood pressure, and ECG among healthy patients and chronic diseases patients. Advanced intraoperative monitoring equipment during surgery helps assess patients' hearts real time in safety for patient comfort and best surgical results. Additionally, monitoring devices post-surgery will help track the recovery, early detection of complications, and minimize hospital readmission rates. Integration of AI and IoT into these devices improves the accuracy of data, patient engagement, and clinician decision-making. On the other hand, adoption of telehealth and remote patient monitoring technologies is growing and allows the continuation of care outside the clinical setting.

"Asia Pacific to grow with the highest CAGR in the Cardiovascular devices market during the forecast period."

The Asia-Pacific region is also expected to experience maximum growth in the cardiovascular devices market in the next few years due to several key factors. Growth is driven by an increasingly aging population, the growing prevalence of cardiovascular diseases, and increased adoption of minimally invasive procedures, especially in countries such as China, Japan, and India. Increased healthcare expenses and development of health infrastructure promote the availability of high-end interventional cardiology services throughout the region.

The break up of the profile of primary participants in the cardiovascular devices market:

• By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%
• By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%.
• By Region: North America - 40%, Europe - 30%, APAC -20%, Latin America - 5%,Middle East & Africa-5%

Key players in the cardiovascular devices market

Some of the prominent players operating in the cardiovascular devices market include Medtronic Plc (Ireland), Abbott Laboratories (US), Boston Scientific Corporation (US), Terumo Corporation (Japan), GE Healthcare Technologies, Inc. (US), Edward Lifesciences Corporation (US), Siemens Healthineers AG (Germany), Johnson & Johnson (US), Baxter International Inc (US), B. Braun SE (Germany), Getinge AB (Sweden), Koninklijke Philips N.V. (Netherlands), Lepu Medical Technology (Beijing) Co., Ltd (China), Nihon Kohden Corporation (Japan), MicroPort Scientific Corporation (China), Japan Lifeline Co., Ltd. (Japan), AngioDynamics, Inc.(US), LifeTech Scientific Corporation (China), Artivion Inc (US), Sahajanand Medical Technologies Limited (India), OrbusNeich Medical Group Holdings Limited (China), BPL Medical Technologies (India), BiotroniK. (Germany),), W.L. Gore & Associates, Inc (US), Canon medical systems corporation (Japan), Picard Medical Company (US).

Research Coverage:

The report analyzes the cardiovascular devices market and aims at estimating the market size and future growth potential of this market based on various segments such as products, indication and end user. The report also includes a product portfolio matrix of various cardiovascular device technologies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall cardiovascular devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report provides insights into the following pointers:

• Of Analysis of key drivers (The increase in prevalence of cardiovascular diseases, The increasing preference for minimally invasive techniques, Technological Advancements Fueling Innovation in Cardiovascular Devices, Rise in Remote Patient Monitoring), restraints (Stringent regulatory guidelines for product approval, Lack of skilled Cardiovascular Healthcare professionals), opportunities (Projected Growth in the Elderly Population, Emerging Opportunities in Biodegradable Cardiovascular Devices) and challenges (Product failures and recalls, Adverse Effects and Complications with usage of implantable cardiovascular devices).
• Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global cardiovascular devicesmarket.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global cardiovascular devices market
• Market Development: Comprehensive information on the lucrative emerging markets by product, indication and enduser.
• Market Diversification: Exhaustive information about new product or product enhancements, growing geographies, recent developments, and investments in the global cardiovascular devices market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of product and services, and capacities of the major competitors in the global cardiovascular devices market.

TABLE OF CONTENTS

A1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKET SEGMENTATION
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 GROWTH FORECAST
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 MARKET RANKING ANALYSIS
• 2.6 STUDY ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
  • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.7.2 SCOPE-RELATED LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 CARDIOVASCULAR DEVICES MARKET OVERVIEW
• 4.2 NORTH AMERICA: CARDIOVASCULAR DEVICES MARKET, BY END USER AND COUNTRY (2023)
• 4.3 CARDIOVASCULAR DEVICES MARKET: REGIONAL MIX, 2024-2029 (USD MILLION)

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising incidence of cardiovascular diseases
    • 5.2.1.2 Increasing accessibility to advanced high-performance devices
    • 5.2.1.3 Growing preference for minimally invasive surgeries
    • 5.2.1.4 Rising technological advancements in cardiovascular devices
    • 5.2.1.5 Increasing trend of remote patient monitoring
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Stringent regulatory guidelines for product approval
    • 5.2.2.2 Shortage of skilled cardiac health professionals
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rising geriatric population and increasing uptake of CVD devices
    • 5.2.3.2 Emergence of biodegradable cardiovascular devices
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Product recalls & failures
    • 5.2.4.2 Complications associated with implantable devices
• 5.3 INDUSTRY TRENDS
  • 5.3.1 MINIMALLY INVASIVE PROCEDURES
  • 5.3.2 WEARABLE TECHNOLOGY AND REMOTE MONITORING
  • 5.3.3 PERSONALIZED MEDICINE
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Transcatheter aortic valve replacement (TAVR)
    • 5.4.1.2 Cardiac mapping systems
    • 5.4.1.3 3D-printed cardiovascular devices
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Robotic-assisted surgeries
    • 5.4.2.2 Advanced catheter systems
    • 5.4.2.3 Imaging technologies
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Regenerative medicine
    • 5.4.3.2 Biomaterials & nanotechnology
    • 5.4.3.3 Big data & cloud computing
• 5.5 PORTER'S FIVE FORCE ANALYSIS
  • 5.5.1 THREAT OF NEW ENTRANTS
  • 5.5.2 BARGAINING POWER OF SUPPLIERS
  • 5.5.3 BARGAINING POWER OF BUYERS
  • 5.5.4 THREAT OF SUBSTITUTES
  • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.6 REGULATORY LANDSCAPE
  • 5.6.1 REGULATORY ANALYSIS
    • 5.6.1.1 North America
      • 5.6.1.1.1 US
      • 5.6.1.1.2 Canada
    • 5.6.1.2 Europe
    • 5.6.1.3 Asia Pacific
    • 5.6.1.4 Latin America
    • 5.6.1.5 Middle East & Africa
  • 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.7 PATENT ANALYSIS
  • 5.7.1 PATENT PUBLICATION TRENDS IN CARDIOVASCULAR DEVICES MARKET
  • 5.7.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.8 TRADE ANALYSIS
• 5.9 PRICING ANALYSIS
• 5.10 KEY CONFERENCES & EVENTS, 2024-2025
• 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.11.2 BUYING CRITERIA
• 5.12 UNMET NEEDS/END-USER EXPECTATIONS IN CARDIOVASCULAR DEVICES MARKET
• 5.13 IMPACT OF AI/GENERATIVE AI ON CARDIOVASCULAR DEVICES MARKET
• 5.14 ECOSYSTEM ANALYSIS
• 5.15 CASE STUDY ANALYSIS
  • 5.15.1 CASE STUDY 1: EVALUATION OF TAVR SYSTEM
  • 5.15.2 CASE STUDY 2: SAFETY & EFFICACY ASSESSMENT OF WATCHMAN DEVICE IN ATRIAL FIBRILLATION
  • 5.15.3 CASE STUDY 3: PERFORMANCE ANALYSIS OF MITRACLIP FOR THE TREATMENT OF MITRAL REGURGITATION
• 5.16 SUPPLY CHAIN ANALYSIS
• 5.17 ADJACENT MARKET ANALYSIS
  • 5.17.1 CARDIAC MONITORING AND RHYTHM MANAGEMENT DEVICES MARKET
• 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.19 CARDIOVASCULAR DEVICES MARKET: INVESTMENT & FUNDING SCENARIO
• 5.20 R&D PIPELINE ANALYSIS

6 CARDIOVASCULAR DEVICES MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 CARDIAC IMAGING & DIAGNOSTIC DEVICES
  • 6.2.1 ECG DEVICES
    • 6.2.1.1 Low costs and expanding applications to fuel market
  • 6.2.2 CARDIAC ULTRASOUND IMAGING
    • 6.2.2.1 Growing preference towards minimally invasive techniques to boost demand
  • 6.2.3 CARDIAC COMPUTERIZED TOMOGRAPHY (CT) SCANNERS
    • 6.2.3.1 Increasing preference over other diagnostic imaging methods to drive market
  • 6.2.4 CARDIAC MAGNETIC RESONANCE IMAGING (MRI)
    • 6.2.4.1 Increasing incidence of cardiac diseases to fuel uptake
  • 6.2.5 NUCLEAR CARDIOLOGY SYSTEMS
    • 6.2.5.1 Ability to assess tissue functionality and heart physiology to support market growth
  • 6.2.6 CARDIAC DIAGNOSTIC CATHETERS
    • 6.2.6.1 Rising focus on catheterization procedures to fuel market
• 6.3 CARDIAC RHYTHM MANAGEMENT DEVICES
  • 6.3.1 PACEMAKERS
    • 6.3.1.1 Growing availability of leadless and MRI-safe devices to boost demand
  • 6.3.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD)
    • 6.3.2.1 Increasing prevalence of arrhythmias to drive market
  • 6.3.3 CARDIAC RESYNCHRONIZATION THERAPY (CRT) DEVICES
    • 6.3.3.1 Ability to reduce fatigue and associated heart failure symptoms to boost demand
• 6.4 INTERVENTIONAL CARDIOLOGY DEVICES
  • 6.4.1 CORONARY STENTS
    • 6.4.1.1 Technological advancements in stents to fuel uptake
  • 6.4.2 HEART VALVE DEVICES
    • 6.4.2.1 Increasing prevalence of valve stenosis and regurgitation to fuel market
  • 6.4.3 CLOSURE DEVICES
    • 6.4.3.1 Utilization of self-expandable materials to drive market
  • 6.4.4 SURGICAL CATHETERS
    • 6.4.4.1 Rising adoption of angioplasty procedures to support market growth
  • 6.4.5 GUIDEWIRES
    • 6.4.5.1 Rising uptake in PCI procedures to drive market
  • 6.4.6 OTHER INTERVENTIONAL CARDIOLOGY DEVICES
• 6.5 CARDIAC ASSIST DEVICES
  • 6.5.1 VENTRICULAR ASSIST DEVICES
    • 6.5.1.1 Rising incidence of heart failure to boost market
  • 6.5.2 INTRA-AORTIC BALLOON PUMPS (IABP)
    • 6.5.2.1 Product recalls to restrain market
  • 6.5.3 TOTAL ARTIFICIAL HEART (TAH)
    • 6.5.3.1 Growing product pipeline to fuel market
  • 6.5.4 IMPELLA DEVICES
    • 6.5.4.1 Increasing utility in high-risk procedures to support market growth
• 6.6 ELECTROPHYSIOLOGY DEVICES
  • 6.6.1 EP CATHETERS
    • 6.6.1.1 Rising incidence of chronic heart conditions to drive market
  • 6.6.2 ABLATION SYSTEMS
    • 6.6.2.1 Increasing utilization of radiofrequency ablation procedures to support market growth
  • 6.6.3 3D MAPPING SYSTEM
    • 6.6.3.1 Development of alternative technologies to hinder market
• 6.7 EXTERNAL SUPPORT DEVICES
  • 6.7.1 EXTERNAL DEFIBRILLATORS
    • 6.7.1.1 Adoption of user-friendly AEDs to fuel market
  • 6.7.2 EXTERNAL PACEMAKERS
    • 6.7.2.1 Technological advancements in leadless & implantable pacemakers to restrain market
  • 6.7.3 CARDIAC COMPRESSION DEVICES
    • 6.7.3.1 Reduced CPR rate to restrain market
• 6.8 MONITORING DEVICES
  • 6.8.1 BLOOD PRESSURE MONITORS
    • 6.8.1.1 Portability and ease of use to fuel market
  • 6.8.2 PULSE OXIMETERS
    • 6.8.2.1 Increasing adoption of OTC devices in home care settings to propel market
  • 6.8.3 IMPLANTABLE CARDIAC MONITORS (ICM)
    • 6.8.3.1 Growing focus on RPM to support market

7 CARDIOVASCULAR DEVICES MARKET, BY INDICATION

• 7.1 INTRODUCTION
• 7.2 CORONARY ARTERY DISEASE
  • 7.2.1 ANGINA PECTORIS
    • 7.2.1.1 Growing adoption of implantable monitors and ECG devices for treatment to drive market
  • 7.2.2 MYOCARDIAL INFARCTION
    • 7.2.2.1 Increasing demand for stents in acute cases to fuel market
• 7.3 ARRHYTHMIAS
  • 7.3.1 TACHYCARDIA
    • 7.3.1.1 Rising cardiac electrophysiology procedures to drive market
  • 7.3.2 BRADYCARDIA
    • 7.3.2.1 Rising incidence of OSA to support market growth
• 7.4 STRUCTURAL HEART DISEASE
  • 7.4.1 VALVULAR HEART DISEASE
    • 7.4.1.1 Rising risks of aortic stenosis to drive market
  • 7.4.2 CONGENITAL HEART DISEASE
    • 7.4.2.1 Potential for new therapies to fuel uptake
  • 7.4.3 CARDIOMYOPATHY
    • 7.4.3.1 Uptake of ICDs to drive market
  • 7.4.4 CONGESTIVE HEART FAILURE
    • 7.4.4.1 Growth in geriatric population to fuel market
• 7.5 INFLAMMATORY HEART DISEASE
  • 7.5.1 PERICARDITIS
    • 7.5.1.1 Increasing incidence due to COVID-19 to support market growth
  • 7.5.2 MYOCARDITIS
    • 7.5.2.1 Increasing prevalence of autoimmune diseases to support market growth
  • 7.5.3 ENDOCARDITIS
    • 7.5.3.1 Focus on echocardiography for clinical evaluation to drive market
• 7.6 OTHER CARDIOVASCULAR INDICATIONS

8 CARDIOVASCULAR DEVICES MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 HOSPITALS & CLINCS
  • 8.2.1 HIGH PURCHASING POWER OF HOSPITALS AND RISING NUMBER OF CARDIOVASCULAR PROCEDURES TO DRIVE MARKET
• 8.3 DIAGNOSTIC LABORATORIES
  • 8.3.1 RISING FOCUS ON TECHNOLOGICALLY ADVANCED DIAGNOSTIC INSTRUMENTS TO SUPPORT MARKET GROWTH
• 8.4 AMBULATORY SURGERY CENTERS
  • 8.4.1 INCREASING DEMAND FOR OUTPATIENT CARE AND RPM SERVICES TO PROPEL MARKET
• 8.5 OTHER END USERS

9 CARDIOVASCULAR DEVICES MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 Increasing cases of obesity due to sedentary lifestyles to propel market
  • 9.2.3 CANADA
    • 9.2.3.1 Increasing funding for CVD research to support market growth
• 9.3 EUROPE
  • 9.3.1 INCREASING PRODUCT APPROVALS FOR ADVANCED CARDIOVASCULAR DEVICES TO DRIVE MARKET
  • 9.3.2 MACROECONOMIC OUTLOOK FOR EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 LARGE TARGET PATIENT POPULATION AND INCREASING INCIDENCE OF CVD TO PROPEL MARKET
  • 9.4.2 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 BURDEN OF CONGENITAL HEART DISEASES TO DRIVE MARKET
  • 9.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
• 9.6 MIDDLE EAST & AFRICA
  • 9.6.1 RISING HEALTHCARE EXPENDITURE TO SUPPORT MARKET GROWTH
  • 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CARDIOVASCULAR DEVICES MARKET
• 10.3 REVENUE ANALYSIS
• 10.4 MARKET SHARE ANALYSIS
  • 10.4.1 RANKING OF KEY MARKET PLAYERS, 2023
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Region footprint
    • 10.5.5.3 Product footprint
    • 10.5.5.4 Indication footprint
    • 10.5.5.5 End-user footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 10.7 COMPANY VALUATION & FINANCIAL METRICS
  • 10.7.1 COMPANY VALUATION
  • 10.7.2 FINANCIAL METRICS
• 10.8 BRAND/PRODUCT COMPARISON
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT LAUNCHES & APPROVALS
  • 10.9.2 DEALS
  • 10.9.3 EXPANSIONS
  • 10.9.4 OTHER DEVELOPMENTS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 MEDTRONIC
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Product launches & approvals
      • 11.1.1.3.2 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Key strengths
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses & competitive threats
  • 11.1.2 ABBOTT LABORATORIES
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Product launches & approvals
      • 11.1.2.3.2 Deals
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Key strengths
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses & competitive threats
  • 11.1.3 BOSTON SCIENTIFIC CORPORATION
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Product launches & approvals
      • 11.1.3.3.2 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Key strengths
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses & competitive threats
  • 11.1.4 GE HEALTHCARE
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Product launches & approvals
      • 11.1.4.3.2 Deals
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Key strengths
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses & competitive threats
  • 11.1.5 TERUMO CORPORATION
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product launches & approvals
    • 11.1.5.4 MnM view
      • 11.1.5.4.1 Key strengths
      • 11.1.5.4.2 Strategic choices
      • 11.1.5.4.3 Weaknesses & competitive threats
  • 11.1.6 EDWARDS LIFESCIENCES CORPORATION
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Product launches & approvals
      • 11.1.6.3.2 Deals
  • 11.1.7 SIEMENS HEALTHINEERS AG
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Product launches & approvals
  • 11.1.8 JOHNSON AND JOHNSON SERVICES, INC.
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Product launches & approvals
      • 11.1.8.3.2 Deals
  • 11.1.9 SAHAJANAND MEDICAL TECHNOLOGIES LIMITED
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
  • 11.1.10 BAXTER INTERNATIONAL INC
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Deals
  • 11.1.11 ARTIVION, INC.
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
  • 11.1.12 GETINGE AB
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
    • 11.1.12.3 Recent developments
      • 11.1.12.3.1 Product launches & approvals
      • 11.1.12.3.2 Deals
  • 11.1.13 KONINKLIJKE PHILIPS N.V.
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
    • 11.1.13.3 Recent developments
      • 11.1.13.3.1 Product launches & approvals
  • 11.1.14 NIHON KOHDEN CORPORATION
    • 11.1.14.1 Business overview
    • 11.1.14.2 Products offered
  • 11.1.15 BIOTRONIK SE & CO.KG.
    • 11.1.15.1 Business overview
    • 11.1.15.2 Products offered
  • 11.1.16 LEPU MEDICAL TECHNOLOGY(BEIJING) CO., LTD.
    • 11.1.16.1 Business overview
    • 11.1.16.2 Products offered
    • 11.1.16.3 Recent developments
      • 11.1.16.3.1 Product launches & approvals
  • 11.1.17 MICROPORT SCIENTIFIC CORPORATION
    • 11.1.17.1 Business overview
    • 11.1.17.2 Products offered
    • 11.1.17.3 Recent developments
      • 11.1.17.3.1 Product launches & approvals
  • 11.1.18 ANGIODYNAMICS INC.
    • 11.1.18.1 Business overview
    • 11.1.18.2 Products offered
  • 11.1.19 JAPAN LIFELINE CO., LTD.
    • 11.1.19.1 Business overview
    • 11.1.19.2 Products offered
    • 11.1.19.3 Recent developments
      • 11.1.19.3.1 Product launches & approvals
  • 11.1.20 W.L. GORE & ASSOCIATES
    • 11.1.20.1 Business overview
    • 11.1.20.2 Products offered
  • 11.1.21 B. BRAUN SE
    • 11.1.21.1 Business overview
    • 11.1.21.2 Products offered
• 11.2 OTHER PLAYERS
  • 11.2.1 CANON MEDICAL SYSTEMS CORPORATION
  • 11.2.2 PICARD MEDICAL COMPANY
  • 11.2.3 BPL MEDICAL TECHNOLOGIES PVT LTD
  • 11.2.4 LIFETECH SCIENTIFIC CORPORATION
  • 11.2.5 ORBUSNEICH MEDICAL GROUP HOLDINGS LIMITED

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS